Stay updated with breaking news from Precigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Precigen, Inc. (NASDAQ:PGEN – Get Rating) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 22,870,000 shares, an increase of 26.2% from the January 31st total of 18,120,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently […]
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...